Sorafenib, regorafenib, lenvatinib, and cabozantinib share similar mode of actions in that they are multikinase inhibitors that block protein kinases involved in tumor angiogenesis (VEGFRs), oncogenesis (RAS, RAF, KIT, and RET), and metastasis (PDGFR). The gene discussed is PDGFRB; the disease is neoplasm.